JP2024537136A5 - - Google Patents
Info
- Publication number
- JP2024537136A5 JP2024537136A5 JP2024520700A JP2024520700A JP2024537136A5 JP 2024537136 A5 JP2024537136 A5 JP 2024537136A5 JP 2024520700 A JP2024520700 A JP 2024520700A JP 2024520700 A JP2024520700 A JP 2024520700A JP 2024537136 A5 JP2024537136 A5 JP 2024537136A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- pharmaceutical composition
- kras
- pan
- erbb family
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163252534P | 2021-10-05 | 2021-10-05 | |
| US63/252,534 | 2021-10-05 | ||
| PCT/US2022/045621 WO2023059596A1 (en) | 2021-10-05 | 2022-10-04 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH Pan ErbB FAMILY INHIBITORS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024537136A JP2024537136A (ja) | 2024-10-10 |
| JP2024537136A5 true JP2024537136A5 (cg-RX-API-DMAC10.html) | 2025-10-10 |
Family
ID=85803674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024520700A Pending JP2024537136A (ja) | 2021-10-05 | 2022-10-04 | ＫＲＡＳ Ｇ１２Ｄ阻害剤と汎ＥｒｂＢファミリー阻害剤との併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240408099A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4412717A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024537136A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240089340A (cg-RX-API-DMAC10.html) |
| CN (1) | CN118369119A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022359880A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3233567A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL311835A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024004216A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023059596A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021085653A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
| US12702658B2 (en) | 2020-04-24 | 2026-08-11 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C |
| WO2021215544A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| WO2022109487A1 (en) | 2020-11-23 | 2022-05-27 | Merck Sharp & Dohme Corp. | Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant |
| US20260200925A1 (en) * | 2021-11-24 | 2026-07-16 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras mutated proteins |
| WO2025034919A1 (en) * | 2023-08-08 | 2025-02-13 | Quanta Therapeutics, Inc. | Combination therapies with kras modulators |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| KR20260110993A (ko) | 2023-10-09 | 2026-07-14 | 인사이트 코포레이션 | Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합 |
| US20250114346A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| CN122459678A (zh) | 2023-12-29 | 2026-07-24 | 百时美施贵宝公司 | KRAS抑制剂与Treg耗竭剂的组合疗法 |
| WO2026060400A1 (en) * | 2024-09-16 | 2026-03-19 | Quanta Therapeutics, Inc. | Combination therapies with kras modulators |
| US20260137674A1 (en) | 2024-10-23 | 2026-05-21 | Incyte Corporation | Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor |
| WO2026090333A1 (en) | 2024-10-23 | 2026-04-30 | Incyte Corporation | Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104203243A (zh) | 2012-03-19 | 2014-12-10 | 默克专利股份公司 | 具有抗肿瘤活性的6-氧代-1,6-二氢-哒嗪衍生物与其他抗肿瘤化合物的组合 |
| CA3112043A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| CN114615981B (zh) | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂 |
| WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| WO2023284730A1 (en) | 2021-07-14 | 2023-01-19 | Nikang Therapeutics, Inc. | Alkylidene derivatives as kras inhibitors |
-
2022
- 2022-10-04 KR KR1020247014965A patent/KR20240089340A/ko active Pending
- 2022-10-04 CN CN202280077622.7A patent/CN118369119A/zh active Pending
- 2022-10-04 JP JP2024520700A patent/JP2024537136A/ja active Pending
- 2022-10-04 WO PCT/US2022/045621 patent/WO2023059596A1/en not_active Ceased
- 2022-10-04 IL IL311835A patent/IL311835A/en unknown
- 2022-10-04 MX MX2024004216A patent/MX2024004216A/es unknown
- 2022-10-04 CA CA3233567A patent/CA3233567A1/en active Pending
- 2022-10-04 EP EP22879174.5A patent/EP4412717A4/en active Pending
- 2022-10-04 US US18/694,867 patent/US20240408099A1/en active Pending
- 2022-10-04 AU AU2022359880A patent/AU2022359880A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024537140A5 (cg-RX-API-DMAC10.html) | ||
| JP2022548791A5 (cg-RX-API-DMAC10.html) | ||
| JP2025000632A5 (cg-RX-API-DMAC10.html) | ||
| JP2024537139A5 (cg-RX-API-DMAC10.html) | ||
| JP2025000629A5 (cg-RX-API-DMAC10.html) | ||
| JP2024537137A5 (cg-RX-API-DMAC10.html) | ||
| JP2025000630A5 (cg-RX-API-DMAC10.html) | ||
| JP2024540839A5 (cg-RX-API-DMAC10.html) | ||
| FI3849537T3 (fi) | Yhdistelmäterapioita | |
| JP2025512999A5 (cg-RX-API-DMAC10.html) | ||
| JP2022548255A5 (cg-RX-API-DMAC10.html) | ||
| JP2022500381A5 (cg-RX-API-DMAC10.html) | ||
| CN105311030B (zh) | 用于抗肿瘤的螺取代化合物 | |
| JP2022500388A5 (cg-RX-API-DMAC10.html) | ||
| CN101850047B (zh) | 一种治疗湿疹皮炎的中药组合物及其制剂 | |
| Kojonazarov et al. | Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling | |
| JP2022535577A5 (cg-RX-API-DMAC10.html) | ||
| EA200700893A1 (ru) | Предшественники половых стероидов, одни или в сочетании с селективным модулятором эстрогеновых рецепторов, и/или с эстрогенами, и/или ингибитором цгмф-фосфодиэстераз 5 типа для профилактики и лечения вагинальной сухости и половой дисфункции у женщин в постменопаузе | |
| JP2022530866A5 (cg-RX-API-DMAC10.html) | ||
| IL311834A (en) | Combinations of KRAS G12D inhibitors with PI3KA inhibitors and therapeutic methods | |
| IL311863A (en) | Combinations of KRAS G12D inhibitors and irinotecan and therapeutic methods | |
| JP2009506054A5 (cg-RX-API-DMAC10.html) | ||
| CN101698036A (zh) | 一种治疗痔疮的中药、中药巴布剂及其制备方法 | |
| CN103272149B (zh) | 一种防治肛肠病手术后并发症的药物组合物 | |
| IL315645A (en) | Combination therapies comprising a sos1 inhibitor and an egfr inhibitor |